TriangleNCT04465760 · OUTCOME
Time to Detection of Thrombosis
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- From xisomab 3G3 infusion up to end of treatment visit (day 18)
What was measured
Will be reported for those (expected few) subjects with symptomatic CAT.
Analysis population: No participants developed symptomatic CAT.
Groups in this outcome
Supportive Care (Xisomab 3G3)
Patients receive xisomab 3G3 IV or via catheter within 48 hours of catheter placement. Patients then receive standard of care chemotherapy 2 days later. After approximately 2 weeks, patients undergo standard of care ultrasound for possible CAT. Xisomab 3G3: Given IV or via catheter
| Group | Source count |
|---|---|
| Supportive Care (Xisomab 3G3) | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Will be reported for those (expected few) subjects with symptomatic CAT.
- groups
- description
- Patients receive xisomab 3G3 IV or via catheter within 48 hours of catheter placement. Patients then receive standard of care chemotherapy 2 days later. After approximately 2 weeks, patients undergo standard of care ultrasound for possible CAT. Xisomab 3G3: Given IV or via catheter
- id
- OG000
- title
- Supportive Care (Xisomab 3G3)
- population Description
- No participants developed symptomatic CAT.
- reporting Status
- POSTED
- time Frame
- From xisomab 3G3 infusion up to end of treatment visit (day 18)
- title
- Time to Detection of Thrombosis
- type
- OTHER_PRE_SPECIFIED
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice